Tirzepatide (Mounjaro/Zepbound), Testosterone & Male Fertility

Tirzepatide is sold as Mounjaro for type 2 diabetes and Zepbound for weight management, and it is the first dual GIP/GLP-1 receptor agonist — a two-incretin mechanism that produces the largest weight loss of any approved anti-obesity medicine (SURMOUNT-1 mean −20.9% at the 15 mg dose^[12], versus −14.9% for semaglutide 2.4 mg in STEP 1^[11]). That single fact reframes the testosterone question. Because obesity-associated low testosterone reverses in proportion to weight lost — the central finding of the Corona 2013 meta-analysis^[1] — the agent that removes the most fat should, on average, drive the largest testosterone recovery. So for a man with obesity, the honest expected direction on tirzepatide is testosterone up, not down, and plausibly up by more than on semaglutide. The important caveat: this has never been measured head-to-head with a testosterone endpoint, so the “more weight, more testosterone” step is a mechanism-based inference, not a trial result. This article covers both the Mounjaro context (diabetic men, in whom hypogonadism is strikingly common) and the Zepbound weight-management context, and it treats the fertility question honestly — weight loss can improve sperm parameters, but there is no tirzepatide fertility trial. For the sibling molecule, see Ozempic, testosterone, and male fertility.

The honest summary

• In men with obesity, tirzepatide-driven weight loss usually raises testosterone, not lowers it. Obesity is a leading cause of low testosterone in men, and body-weight loss reverts obesity-associated hypogonadotropic hypogonadism, with the testosterone gain scaling to the amount of weight lost (Corona 2013^[1]).
• Tirzepatide loses the most weight, so it may recover the most testosterone. SURMOUNT-1 delivered −20.9%^[12] — larger than semaglutide's STEP 1 −14.9%^[11]. If the testosterone response tracks weight lost, the dual agonist plausibly produces the biggest rise. This is an extrapolation: no trial has compared the two drugs on a testosterone endpoint.
• There is no established direct GIP/GLP-1 effect that suppresses testosterone in humans. No published trial shows tirzepatide directly lowering the hypothalamic-pituitary-gonadal (HPG) axis. The hormone change men experience is the well-documented weight-loss-raises-testosterone effect, working through fat loss.
• The mechanism is aromatase and the HPG axis. Adipose tissue converts testosterone to estradiol and its adipokine load blunts GnRH pulses; both lower testosterone in heavier men and both partly reverse with weight loss (Grossmann 2020^[3], EMAS Camacho 2013^[2]).
• The Mounjaro angle: diabetic hypogonadism is very common. Low testosterone is disproportionately frequent in men with type 2 diabetes and obesity, so a Mounjaro patient is a prime candidate for the weight-loss-driven testosterone recovery — but glycemic and metabolic improvement is a co-traveller, not a separate direct hormone effect.
• Where the “lowering” fear comes from. Severe, rapid caloric restriction can transiently perturb reproductive hormones — but that is crash-dieting and very low energy-availability physiology, not the gradual 0.5–1 kg/week outcome of a properly titrated tirzepatide.
• Male fertility / sperm: limited but reassuring direction. Higher BMI is linked to worse semen parameters (Sermondade 2013^[5]); weight loss may improve semen quality in obese subfertile men (Pereira 2025^[6]). The GLP-1/GIP-specific human reproductive evidence is early (Deameh 2026^[7]; Merhi 2026^[8]) — no strong human signal of harm, and no tirzepatide fertility RCT.
• Confirm before concluding. Diagnose low testosterone with two morning total-T draws plus symptoms (Bhasin 2018^[9]; harmonized lower limit ~264 ng/dL, Travison 2017^[10]); for fertility, the test is a semen analysis, not a testosterone level.

Why tirzepatide is a different weight-loss lever from semaglutide

Semaglutide (Ozempic, Wegovy) is a single GLP-1 receptor agonist. Tirzepatide (Mounjaro, Zepbound) adds a second incretin: it agonizes both the GIP and the GLP-1 receptor. The clinical consequence that matters for this topic is simple — the dual mechanism produces more weight loss. In the head-to-head SURMOUNT and SURPASS programs and their pivotal placebo-controlled trials, tirzepatide 15 mg reached a mean of about −20.9% body weight in adults with obesity (SURMOUNT-1^[12]), the highest average loss reported for any approved anti-obesity drug, compared with about −14.9% for semaglutide 2.4 mg in STEP 1^[11].

Why does that reframe the testosterone question? Because the testosterone benefit of losing weight is dose-dependent on the weight itself. The Corona 2013 meta-analysis^[1] found that the rise in total testosterone is proportional to the amount of weight lost — diet produced smaller gains, bariatric surgery (the largest loss) produced the largest gains. Tirzepatide sits between structured lifestyle programs and bariatric surgery on the weight-loss spectrum, closer to surgery than any prior drug. If the testosterone response is a function of fat removed, the dual agonist should sit correspondingly high on the testosterone-recovery curve. That is the core, defensible thesis of this article — and also its main limitation, because no one has run the trial that measures it directly.

Why obesity lowers testosterone — the mechanism that makes the direction predictable

Obesity lowers testosterone in men through two converging pathways, and understanding them is what makes tirzepatide's expected effect predictable:

1. Aromatization. Adipose tissue expresses aromatase, the enzyme that converts testosterone to estradiol. More fat mass means more peripheral conversion, so a heavier man carries lower circulating testosterone and higher estradiol than a leaner peer even with structurally normal testes.
2. HPG-axis suppression. Higher estradiol plus adipokine and inflammatory signals (leptin, IL-6, TNF-alpha) blunt hypothalamic GnRH pulse frequency, lowering pituitary LH and therefore Leydig-cell testosterone output. The result is the classic “functional” or hypogonadotropic hypogonadism of obesity: low testosterone with normal-to-low LH and a structurally normal pituitary.

Both pathways are at least partly reversible. Strip out the excess adipose tissue and you strip out the excess aromatase and the suppressive adipokine load — which is exactly why weight loss raises testosterone. Grossmann 2020^[3] is the modern review of this obesity-hypogonadism phenotype and its metabolic reversibility. The clinical implication for tirzepatide is direct: the drug that produces the largest reduction in fat mass acts most forcefully on both suppressive pathways at once.

The evidence: weight loss raises testosterone (and more weight tends to mean more testosterone)

Corona 2013 (Eur J Endocrinol)^[1] is the central reference and the one that does the most work for the tirzepatide argument. This systematic review and meta-analysis pooled weight-loss interventions (low-calorie diet and bariatric surgery) in men and found that body-weight loss reverts obesity-associated hypogonadotropic hypogonadism, with the magnitude of the testosterone increase proportional to the weight lost. Bariatric surgery — the largest weight loss — produced the largest testosterone gains; diet produced smaller but still meaningful increases. Estradiol fell and SHBG rose concordantly, which raises calculated free testosterone as well. The dose-response is the crux: it is precisely why an agent that loses ~21% of body weight should be expected to outperform one that loses ~15% on this endpoint.

EMAS longitudinal data (Camacho 2013)^[2] followed several thousand middle-aged and older European men over time. Weight gain accelerated the age-related fall in testosterone; weight loss greater than ~15% of body weight blunted or reversed it, with mean total-testosterone increases on the order of 2–3 nmol/L (roughly 60–90 ng/dL) in men who achieved large sustained loss, alongside falling estradiol and rising SHBG. Note the threshold: EMAS found the clearest testosterone benefit above ~15% weight loss — a band that tirzepatide reaches on average and that many patients exceed, whereas diet-only programs frequently fall short of it.

Khoo 2013 (J Sex Med)^[4] adds the exercise angle: obese men randomized to higher-volume moderate-intensity exercise improved both sexual function and total testosterone in a dose-response fashion, even at modest weight loss. The point for the tirzepatide reader is that the testosterone benefit of weight loss is robust across how the weight comes off — diet, exercise, surgery — so there is no mechanistic reason to expect dual-agonist-driven weight loss to behave differently, and every reason to expect its larger magnitude to help.

The Mounjaro angle: diabetic hypogonadism is common, and tirzepatide targets its root cause

Mounjaro is the type 2 diabetes brand of tirzepatide, and the diabetic population is where the testosterone story is most clinically loaded. Low testosterone is strikingly common in men with type 2 diabetes and obesity — the combination of excess adiposity, insulin resistance, and chronic inflammation drives the same aromatase-and-HPG suppression described above, layered on top of the metabolic disease. A large share of men with T2D and obesity meet criteria for functional hypogonadism, and much of it is the reversible, obesity-driven kind rather than primary testicular failure.

That makes a Mounjaro patient close to the ideal candidate for the weight-loss-driven testosterone recovery. Tirzepatide attacks the root cause — it produces large weight loss and improves insulin sensitivity, both of which reduce the adipose-tissue burden that was suppressing the HPG axis. The honest framing is that the testosterone benefit still runs through fat loss and metabolic improvement, not through a separate direct hormonal action of the drug; glycemic control is a co-traveller of weight loss here, not an independent testosterone lever with human evidence behind it. But for a diabetic man with functional hypogonadism, the practical expectation is favorable: the same intervention that improves his glucose is the one most likely to lift his testosterone.

Does tirzepatide directly suppress the HPG axis? No established human effect

Separate from the weight-loss-driven changes, the narrower scientific question is whether GIP/GLP-1 signaling itself does something to the reproductive axis independent of fat loss. As of 2026, there is no established direct suppressive effect of tirzepatide on the human HPG axis. The recent systematic review by Deameh 2026 (J Sex Med)^[7] of GLP-1-based therapies' effects on male reproductive hormones, semen parameters, and metabolic outcomes found the available human data point toward neutral-to-favorable hormonal changes consistent with the weight-loss mechanism, with the literature still thin and heterogeneous. No human trial demonstrates that tirzepatide lowers testosterone through a direct receptor effect.

Incretin receptors have been identified in reproductive tissue in preclinical work, and some animal experiments suggest incretin signaling may even be supportive of certain reproductive functions. But receptor-mapping and animal models do not establish a clinical effect in men, in either direction. Merhi 2026 (Sex Med Rev)^[8], a narrative review of GLP-1-based drugs and sexual function in both sexes, reaches the same cautious bottom line: a plausible biological substrate for a direct effect exists, but it has not been shown to lower testosterone or harm fertility in humans. Because tirzepatide adds GIP-receptor agonism on top of GLP-1, its dual mechanism has less human reproductive data than semaglutide, not more — another reason to lean on the well-characterized weight-loss pathway rather than speculate about direct hormonal effects.

Tirzepatide and male fertility / sperm: what is and isn't known

This is the part of the topic where overclaiming is most tempting and least justified — and where tirzepatide specifically has essentially no direct human data. Here is the layered evidence, from best-supported to most uncertain:

Obesity is associated with worse semen quality. Sermondade 2013 (Hum Reprod Update)^[5], an updated systematic review and collaborative meta-analysis, found a relationship between higher BMI and abnormal sperm counts, including oligozoospermia and azoospermia. Obesity also travels with low testosterone, higher estradiol, erectile dysfunction, and metabolic disease — a cluster that can sit alongside reduced fertility.

Weight loss may improve semen quality in obese men. Pereira 2025 (Hum Reprod)^[6] reviewed weight-loss interventions for obesity-related male infertility and described improvements in reproductive hormones and, in some studies, semen parameters with significant weight loss — while emphasizing that the human intervention data are limited and not uniformly positive. Since tirzepatide produces the deepest weight loss of any drug, it is the agent most likely to reach the weight thresholds where these semen improvements have been observed — but this is inference from the weight-loss literature, not from any tirzepatide fertility study.

Tirzepatide-specific human reproductive data essentially does not exist. The Deameh 2026 systematic review^[7] and the Merhi 2026 narrative review^[8] both conclude that the human evidence on incretin-based therapies and male reproductive function — including semen parameters — is emerging, small, and heterogeneous, with an explicit call for further research; the dual-agonist evidence base is thinner still. There is no tirzepatide fertility RCT and no strong human evidence that tirzepatide harms sperm. The favorable indirect mechanism (large weight loss improves the metabolic milieu) coexists with genuine uncertainty about any direct effect.

Can you take tirzepatide and testosterone (TRT) together?

Yes — this is a common and biologically sensible combination for a man who has both obesity and confirmed hypogonadism, and there is no known pharmacokinetic interaction between testosterone and tirzepatide. Testosterone is a steroid hormone; tirzepatide is a peptide drug cleared by general proteolysis and renal routes. They do not compete on a shared metabolic pathway.

The clinical logic mirrors the semaglutide case but is arguably sharper for tirzepatide because of the magnitude of its weight loss. Tirzepatide produces the calorie deficit and the fat loss, while testosterone (in a man with genuinely low testosterone) helps preserve lean mass and shifts body composition toward muscle. Because deeper total weight loss carries a larger absolute lean-mass-loss component, the lean-mass-preservation argument for pairing testosterone with the highest-efficacy weight-loss drug is the strongest rationale for combining them in a hypogonadal man. The caveats are unchanged from any TRT decision: confirm hypogonadism properly first, monitor hematocrit, PSA, and lipids, and remember that exogenous testosterone suppresses spermatogenesis — so for a man who wants to conceive, TRT is the wrong tool and gonadotropin-preserving alternatives should be discussed. The combination is not RCT-validated for weight outcomes; the data are observational and extrapolated.

When to check labs and see a doctor

• Confirm before concluding. If you suspect low testosterone, the diagnosis requires two morning (before 10 AM) total-testosterone measurements below the lab's reference range plus consistent symptoms, per the Endocrine Society 2018 guideline (Bhasin 2018^[9]). A single afternoon value is not a diagnosis. Harmonized reference ranges (Travison 2017^[10]) put the lower normal limit for healthy young men around 264 ng/dL.
• Re-check after meaningful weight loss. Because tirzepatide often drives weight loss past the ~15–20% band where testosterone gains are clearest, a man with baseline obesity-associated low testosterone should have it re-measured after sustained loss — functional hypogonadism frequently improves, sometimes enough to avoid exogenous testosterone entirely.
• For fertility questions, order a semen analysis. Testosterone level and fertility are different questions. A man worried about sperm should get a semen analysis (with repeat testing, since parameters vary) rather than inferring fertility from a hormone panel.
• See a clinician for new or persistent symptoms. Low libido, erectile dysfunction, fatigue, or loss of morning erections deserve evaluation that includes testosterone but also screens for the common confounders — sleep apnea, depression, alcohol, medications, and uncontrolled diabetes (especially relevant for Mounjaro patients).
• Planning conception? Discuss tirzepatide timing and any washout with your clinician, note the oral-contraceptive interaction on the partner side, and do not start exogenous testosterone if near-term fertility matters.

Compare GLP-1 and dual-agonist providers

Many telehealth platforms that prescribe tirzepatide (or compounded alternatives) also offer testosterone and men's-health services through the same membership, which is convenient but not a substitute for a proper hypogonadism workup. Confirm clinician credentials, the labs drawn before any testosterone prescription, and pharmacy sourcing before committing.

Bottom line

• In men with obesity, tirzepatide-driven weight loss typically raises testosterone, because it reverses obesity-associated hypogonadism (Corona 2013^[1], EMAS Camacho 2013^[2], Grossmann 2020^[3]). The fear that “Mounjaro lowers testosterone” has the direction backwards for this population.
• Because tirzepatide produces the largest weight loss of any approved agent (SURMOUNT-1 −20.9%^[12] vs STEP 1 −14.9%^[11]) and the testosterone gain scales with weight lost, the dual agonist plausibly recovers more testosterone than semaglutide — but this has never been tested head-to-head with a testosterone endpoint.
• There is no established direct suppressive effect of tirzepatide on the human HPG axis (Deameh 2026^[7], Merhi 2026^[8]); incretin receptors in reproductive tissue are animal/basic-science findings, not human evidence of harm.
• The Mounjaro context matters: hypogonadism is common in men with type 2 diabetes and obesity, and tirzepatide targets its reversible root cause via weight loss and improved insulin sensitivity.
• Male fertility: obesity is linked to worse semen quality (Sermondade 2013^[5]); weight loss may improve it (Pereira 2025^[6]); there is no tirzepatide fertility RCT and no strong evidence of harm — emerging, not settled. Exogenous testosterone suppresses sperm and is the wrong tool if conception is near-term.
• Confirm low testosterone with two morning draws plus symptoms (Bhasin 2018^[9]; Travison 2017^[10]); use a semen analysis for fertility; discuss tirzepatide timing and the oral-contraceptive interaction with a clinician if planning conception.

Related research

• Ozempic, testosterone, and male fertility — the single-agonist (semaglutide) companion to this article, with the same evidence base and the ~15% weight-loss context
• GLP-1s and erectile dysfunction — the weight-loss-to-ED-improvement chain and the sildenafil/tadalafil interaction question
• Does weight loss reverse erectile dysfunction? — the randomized and surgical evidence that meaningful weight loss restores erectile function in obese men
• GLP-1s, libido, and sex drive — the cross-drug overview of desire and sexual function on incretin therapies
• “Mounjaro penis” explained and “Zepbound penis” explained — the brand-specific genital-changes companions for tirzepatide
• “Wegovy penis” and “Ozempic penis” — the semaglutide-brand equivalents
• Tirzepatide and sex drive in women — the female-side companion covering the Zepbound/Mounjaro weight-loss-and-sexual-function evidence

Important disclaimer. This article is educational and does not constitute medical advice. It does not establish that tirzepatide is safe or unsafe for fertility in any individual; the human reproductive data are limited and emerging, and no tirzepatide fertility trial exists. The claim that tirzepatide raises testosterone more than semaglutide is a mechanism-based inference from weight-loss data, not a head-to-head trial result. Do not start, stop, or change any prescription medication — including tirzepatide or testosterone — based on this article. Diagnosis of hypogonadism requires two morning total-testosterone values below the lab's reference range plus consistent symptoms; fertility is assessed with a semen analysis, not a testosterone level. Men planning conception should discuss tirzepatide timing and any washout with a clinician, note the oral-contraceptive interaction on the partner side, and should not begin exogenous testosterone if near-term fertility matters. PMIDs were independently verified against the PubMed E-utilities API on 2026-06-30.

Last verified: 2026-06-30. Next review: every 12 months, or sooner if a randomized tirzepatide trial with a pre-specified testosterone or semen-analysis endpoint is published.